₹1.49 for Q4, marking a 14.58% increase year-over-year. This positive EPS growth reflects well on the company's profitability.Shalby's stock performance has shown mixed results with -0.7% return in the last week, -12.01% return in the last 6 months, and -10.67% Year-to-Date return, reflecting market volatility.With a market capitalization of ₹2897.41 Cr and a 52-week high/low of ₹339.5 & ₹136.5 respectively, Shalby continues to be a prominent player in the healthcare sector.Analysts covering Shalby have provided positive ratings, with 1 analyst giving a Buy rating and 1 analyst giving a Strong Buy rating as of 31 May, 2024.
Read more on livemint.com